Frank W. Leebeek, MD PhD

Internist-hematologist, Professor
Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
Rotterdam, Zuid-Holland, Netherlands

Presentation(s):

• OC 01.5 - People with mild hemophilia are at risk of joint disease: the nationwide cohort HiN-6 Study

  Saturday, June 22, 2024
  14:00 – 14:15 ICT

• PB0279 - Feasibility, measurement properties and relevance of generic PROMIS item banks in adults with von Willebrand disease, platelet function disorders, and rare bleeding disorders

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0280 - Patient perspective of the burden and severity of von Willebrand disease

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0274 - Re-establishing von Willebrand Factor production in endothelial cells derived from von Willebrand Disease type 3 canine models through CRISPR-Cas9 mediated gene editing

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 32.1 - Risk of CAR T-cell therapy-related thrombosis and bleeding: preliminary results of the multicenter ‘Follow that CAR’ registry

  Monday, June 24, 2024
  09:30 – 09:45 ICT

• OC 32.3 - Low-molecular-weight heparin for the prevention of venous thromboembolism in adults with newly diagnosed acute lymphoblastic leukemia; prospective side-study of the HOVON-100 trial

  Monday, June 24, 2024
  10:00 – 10:15 ICT

• OC 37.1 - Advanced hemostasis testing by quantitative proteomics

  Monday, June 24, 2024
  09:30 – 09:45 ICT

• OC 58.2 - Allele specific knock-out of mutant Von Willebrand factor in heterozygous Von Willebrand disease type 2A patient-derived ECFCs

  Tuesday, June 25, 2024
  09:45 – 10:00 ICT

• OC 61.2 - Determinants of successful immune tolerance induction in people with severe hemophilia A

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT

• SOA 28.3 - Prophylaxis including non-replacement therapy

  Wednesday, June 26, 2024
  09:20 – 09:40 ICT

• OC 73.4 - Personalized treatment by pharmacokinetic-guided dosing in von Willebrand disease; A prospective multicenter study, OPTI-CLOT/To WiN study

  Wednesday, June 26, 2024
  11:00 – 11:15 ICT